PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
BRCA
PARP-I
Poly-ADP ribose polymerase
radiotherapy
synthetic lethality
toxicity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Oct 2021
27 Oct 2021
Historique:
received:
28
09
2021
revised:
18
10
2021
accepted:
25
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
14
11
2021
Statut:
epublish
Résumé
Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) is unclear. We conducted a literature analysis with the aim to evaluate the efficacy and safety profile of a combination with RT and PARP-I. The key issues for the current review were expressed in two questions according to the Population, Intervention, Control, Outcome (PICO) criteria: 1. What is the outcome and 2. What is the toxicity in patients treated with a combination of PARP-I and RT for a newly diagnosed or recurrent tumors? A total of 12 clinical studies met the inclusion criteria including seven single-arm dose-escalation phase I studies, two phase II (two- and three-arms controlled trials) trials, one parallel-arm phase I study, and two phase I/II studies published between 2015 and 2021. RT was performed with photon beams and several schedules according to the clinical situation. The acute toxicity ≥ grade 3 ranged between 25% and >96%, which was divided into hematological or non-hematological adverse events. despite the heterogeneity of the evaluated patient populations and tumor types, and the limited number of the studies, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear.
Sections du résumé
BACKGROUND
BACKGROUND
Despite the large use of inhibitors of Poly-ADP ribose polymerase (PARP-I), the feasibility and safety of their combination with radiotherapy (RT) is unclear.
AIM
OBJECTIVE
We conducted a literature analysis with the aim to evaluate the efficacy and safety profile of a combination with RT and PARP-I.
METHOD
METHODS
The key issues for the current review were expressed in two questions according to the Population, Intervention, Control, Outcome (PICO) criteria: 1. What is the outcome and 2. What is the toxicity in patients treated with a combination of PARP-I and RT for a newly diagnosed or recurrent tumors?
RESULTS
RESULTS
A total of 12 clinical studies met the inclusion criteria including seven single-arm dose-escalation phase I studies, two phase II (two- and three-arms controlled trials) trials, one parallel-arm phase I study, and two phase I/II studies published between 2015 and 2021. RT was performed with photon beams and several schedules according to the clinical situation. The acute toxicity ≥ grade 3 ranged between 25% and >96%, which was divided into hematological or non-hematological adverse events.
CONCLUSIONS
CONCLUSIONS
despite the heterogeneity of the evaluated patient populations and tumor types, and the limited number of the studies, this review suggests that a combination approach is feasible even though the efficacy profile remains unclear.
Identifiants
pubmed: 34771545
pii: cancers13215380
doi: 10.3390/cancers13215380
pmc: PMC8582502
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Anticancer Res. 2016 May;36(5):2055-64
pubmed: 27127105
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):767-775
pubmed: 29413287
Lancet Oncol. 2019 Jan;20(1):e15-e28
pubmed: 30614472
Clin Cancer Res. 2021 Mar 1;27(5):1256-1266
pubmed: 33262140
Mol Cancer Ther. 2006 Mar;5(3):564-74
pubmed: 16546970
Indian J Sex Transm Dis AIDS. 2010 Jan;31(1):47-50
pubmed: 21808439
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Clin Cancer Res. 2019 Jul 1;25(13):3759-3771
pubmed: 30760478
Cancers (Basel). 2020 Oct 17;12(10):
pubmed: 33080914
J Neurooncol. 2015 Apr;122(2):409-17
pubmed: 25682091
Mol Cancer Res. 2018 Jul;16(7):1092-1102
pubmed: 29592899
Science. 2017 Mar 17;355(6330):1152-1158
pubmed: 28302823
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1188-97
pubmed: 18954712
Int J Cancer. 2021 Nov 15;149(10):1828-1832
pubmed: 34270809
J Neurooncol. 2017 Jan;131(1):105-115
pubmed: 27655223
Clin Transl Radiat Oncol. 2019 Dec 28;21:56-61
pubmed: 31993510
Front Pharmacol. 2020 Mar 03;11:170
pubmed: 32194409
Neuro Oncol. 2021 Oct 1;23(10):1736-1749
pubmed: 33984151
EBioMedicine. 2019 Feb;40:375-381
pubmed: 30635165
IUBMB Life. 2017 Dec;69(12):929-937
pubmed: 29171189
Lancet Gastroenterol Hepatol. 2017 Jun;2(6):418-426
pubmed: 28497757
Cancer Sci. 2012 Jun;103(6):1045-50
pubmed: 22404155
Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):436-440
pubmed: 32971187
Invest New Drugs. 2020 Feb;38(1):181-193
pubmed: 31650446
J Clin Oncol. 2018 May 1;36(13):1317-1322
pubmed: 29558281
Int J Mol Sci. 2018 Nov 28;19(12):
pubmed: 30487462
Neuro Oncol. 2020 Jun 9;22(6):875-885
pubmed: 32009149
Cancer. 2018 Jun 15;124(12):2498-2506
pubmed: 29660759
Oncotarget. 2017 Jul 7;8(40):69105-69124
pubmed: 28978184
J Bone Oncol. 2019 Jun 20;17:100246
pubmed: 31312595
BMC Health Serv Res. 2014 Nov 21;14:579
pubmed: 25413154
Clin Lung Cancer. 2021 Jul;22(4):313-323.e1
pubmed: 33745865
Gynecol Oncol. 2017 Mar;144(3):486-490
pubmed: 28109627
Cell Cycle. 2005 Sep;4(9):1176-8
pubmed: 16123586
Clin Cancer Res. 2018 Oct 15;24(20):4949-4959
pubmed: 30084837